|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
143,000,000 |
Market
Cap: |
2.08(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$11.47 - $31.58 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1228 |
Guru Rank Value : -1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
296,265 |
582,024 |
Total Sell Value |
$0 |
$0 |
$7,657,639 |
$13,681,114 |
Total People Sold |
0 |
0 |
6 |
7 |
Total Sell Transactions |
0 |
0 |
25 |
66 |
End Date |
2025-04-13 |
2025-01-10 |
2024-07-12 |
2023-07-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Watts Ryan J. |
President and CEO |
• • – |
2025-07-09 |
4 |
AS |
$15.00 |
$7,429,230 |
D/D |
(495,282) |
253,071 |
|
-3% |
|
Watts Ryan J. |
President and CEO |
• • – |
2025-07-09 |
4 |
OE |
$0.68 |
$520,792 |
D/D |
495,282 |
748,353 |
|
- |
|
Baker Julian |
|
– • – |
2025-06-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,731,695 |
|
10% |
|
Schenkein David P |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
15,257 |
|
- |
|
Cook Jennifer E. |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
26,075 |
|
- |
|
Klein Peter S |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
27,533 |
|
- |
|
Flatley Jay T |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
16,220 |
|
- |
|
Tessier-Lavigne Marc |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
1,886,576 |
|
- |
|
Baker Julian |
|
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
I/I |
21,130 |
3,415,958 |
|
- |
|
Thornberry Nancy |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
24,717 |
|
- |
|
Krognes Steve E. |
Director |
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,037 |
31,794 |
|
- |
|
Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-07 |
4 |
S |
$20.81 |
$60,495 |
D/D |
(2,907) |
244,308 |
|
34% |
|
Krognes Steve E. |
Director |
– • – |
2025-01-07 |
4 |
S |
$20.81 |
$69,485 |
D/D |
(3,339) |
25,757 |
|
34% |
|
Ho Carole |
Chief Medical Officer |
• – – |
2025-01-07 |
4 |
S |
$20.81 |
$60,495 |
D/D |
(2,907) |
175,673 |
|
34% |
|
Watts Ryan J. |
President and CEO |
• • – |
2025-01-07 |
4 |
S |
$20.81 |
$159,197 |
D/D |
(7,650) |
253,071 |
|
34% |
|
Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-06 |
4 |
S |
$20.22 |
$247,796 |
D/D |
(12,255) |
247,215 |
|
30% |
|
Ho Carole |
Chief Medical Officer |
• – – |
2025-01-06 |
4 |
S |
$20.22 |
$247,796 |
D/D |
(12,255) |
178,580 |
|
30% |
|
Watts Ryan J. |
President and CEO |
• • – |
2025-01-06 |
4 |
S |
$20.22 |
$591,759 |
D/D |
(29,266) |
260,721 |
|
30% |
|
Watts Ryan J. |
President and CEO |
• • – |
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
54,180 |
289,987 |
|
- |
|
Schuth Alexander O. |
COFO and Secretary |
• – – |
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
54,180 |
259,470 |
|
- |
|
Ho Carole |
Chief Medical Officer |
• – – |
2025-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
54,180 |
190,835 |
|
- |
|
Sato Vicki L |
Director |
– • – |
2025-01-02 |
4 |
AS |
$20.91 |
$64,403 |
D/D |
(3,080) |
107,976 |
|
-33% |
|
Krognes Steve E. |
Director |
– • – |
2024-12-31 |
4 |
AS |
$20.25 |
$607,500 |
D/D |
(30,000) |
29,096 |
|
-30% |
|
Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-12-27 |
4 |
OE |
$5.28 |
$35,418 |
D/D |
6,708 |
205,290 |
|
- |
|
Ho Carole |
Chief Medical Officer |
• – – |
2024-11-25 |
4 |
OE |
$0.68 |
$12,135 |
D/D |
17,845 |
136,655 |
|
- |
|
475 Records found
|
|
Page 1 of 19 |
|
|